Aurinia Pharmaceuticals (AUPH) Receivables - Net (2016 - 2026)

Aurinia Pharmaceuticals' Receivables - Net history runs 10 years deep, the most recent figure standing at $49.2 million for Q1 2026.

• Quarterly Receivables - Net rose 21.87% year-over-year to $49.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $49.2 million (up 21.87% YoY) and the FY2025 annual result came in at $41.5 million, up 13.44% from the prior year.
• Receivables - Net was $49.2 million for Q1 2026 at Aurinia Pharmaceuticals, up from $41.5 million in the prior quarter.
• Across five years, Receivables - Net topped out at $49.2 million in Q1 2026 and bottomed at $13.5 million in Q4 2022.
• A 5-year average of $30.8 million and a median of $30.7 million in 2025 frame the typical range for Receivables - Net.
• Annual changes were most pronounced in 2022 — Receivables - Net surged 1618.7% — and 2025, when it retreated 15.77%.
• Aurinia Pharmaceuticals' Receivables - Net stood at $13.5 million in 2022, then surged by 78.44% to $24.1 million in 2023, then jumped by 51.7% to $36.5 million in 2024, then climbed by 13.44% to $41.5 million in 2025, then rose by 18.63% to $49.2 million in 2026.
• Business Quant data shows AUPH's Receivables - Net at $49.2 million in Q1 2026, $41.5 million in Q4 2025, and $30.7 million in Q3 2025.